Document Detail

Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels.
MedLine Citation:
PMID:  16516598     Owner:  NLM     Status:  MEDLINE    
This study evaluated the safety, tolerability, and efficacy of statin therapy in patients with heart failure secondary to inflammatory dilated cardiomyopathy and moderately elevated low-density lipoprotein cholesterol levels. Seventy-four patients were randomized to receive atorvastatin 40 mg/day or conventional treatment for heart failure. After 6 months of therapy, the predefined primary efficacy end point (an increase of >5% in the absolute left ventricular ejection fraction and > or =2 selected criteria by echocardiography and a decrease in New York Heart Association functional class) was significant in the statin-treated patients (p = 0.004). Among secondary efficacy parameters, the quality-of-life index showed a trend suggesting the benefit of statin therapy (p = 0.055). In conclusion, the results of this study demonstrate that treatment with atorvastatin in addition to standard therapy for heart failure may significantly improve clinical outcomes in this cohort of patients.
Romuald Wojnicz; Krzysztof Wilczek; Ewa Nowalany-Kozielska; Bozena Szyguła-Jurkiewicz; Jolanta Nowak; Lech Poloński; Krzysztof Dyrbuś; Arkadiusz Badziński; Gabriela Mercik; Marian Zembala; Jan Wodniecki; Marius M Rozek
Related Documents :
20974318 - Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed i...
20837928 - Preoperative atorvastatin treatment in cabg patients rapidly improves vein graft redox ...
20206788 - Results of a retrospective database analysis of adherence to statin therapy and risk of...
19746248 - Role of ankle-brachial pressure index as a predictor of coronary artery disease severit...
15233698 - Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients wit...
12568188 - Gastrointestinal quality of life following laparoscopic vertical banded gastroplasty.
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2006-02-03
Journal Detail:
Title:  The American journal of cardiology     Volume:  97     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-03-06     Completed Date:  2006-04-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  899-904     Citation Subset:  AIM; IM    
3rd Department of Cardiology, Silesian Center for Heart Disease, Zabrze, Poland. wojnicz@dom.zab
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiomyopathy, Dilated / complications*,  drug therapy
Cholesterol, LDL / blood*,  drug effects
Drug Therapy, Combination
Endpoint Determination
Evaluation Studies as Topic
Heart Failure / drug therapy,  etiology*
Heptanoic Acids / therapeutic use*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hypercholesterolemia / complications,  drug therapy*
Myocardium / pathology
Pyrroles / therapeutic use*
Quality of Life
Treatment Outcome
Ventricular Function, Left / drug effects
Reg. No./Substance:
0/Cholesterol, LDL; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 110862-48-1/atorvastatin
Comment In:
Am J Cardiol. 2006 Sep 1;98(5):707   [PMID:  16923467 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Yield of transesophageal echocardiography for nonbacterial thrombotic endocarditis and other cardiac...
Next Document:  Aortic root dilation and aortic elastic properties in children after repair of tetralogy of Fallot.